about
Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in miceMechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.Emergence of protein kinase CK2 as a key target in cancer therapyProtein kinase CK2 inhibition induces cell death via early impact on mitochondrial function.Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapyProtein kinase CK2 in health and disease: CK2: a key player in cancer biologyGrowth inhibition and apoptosis in cancer cells induced by polyphenolic compounds of Acacia hydaspica: Involvement of multiple signal transduction pathways.CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.Evaluation of protein kinase CK2 as a therapeutic target for squamous cell carcinoma of cats.Improving Health Care for Veterans With Gulf War IllnessGulf War Illness-associated increases in blood levels of interleukin 6 and C-reactive protein: biomarker evidence of inflammationCK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFκB p65 ExpressionCDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma CellsProtein kinase CK2 impact on intracellular calcium homeostasis in prostate cancer
P50
Q28543800-F62DA5F4-D0EC-43B7-B4AF-1DA147093315Q34020978-4D3F6B07-AF07-4B81-A882-3F993643B90BQ34046848-B53AE869-7356-4F3A-A2BE-DCB3197FE66AQ34353356-A4A8FD50-3531-48B5-969E-3D6FDFF0C774Q35132090-C156B5C7-756F-4FF7-810A-20EE3D181D21Q35270830-17701B56-B2F9-4585-B2A4-19501807763AQ36686697-7B36D75C-E8EC-49A4-838F-ED18E5EE1181Q37641686-BCE1C9CC-EF12-436B-9A68-D7306264A026Q37731329-93A87C90-7826-4B62-A122-E71D45A53129Q38740809-21ECF328-8DBF-4342-907E-0B59F5707DBCQ48048218-E79A79BF-BC76-406F-ABD1-FD34304ECEF0Q48713759-A5B4F832-89BF-455B-8E36-2531B85474ECQ64277158-5790B9E7-478A-47D3-8265-79B668A17C1BQ92091728-1D37D32A-AB97-480F-8858-DC8237E26CE6Q92733338-A3D560FB-E2F7-41C6-94F9-798B3B84FDBBQ93103354-7E218E65-24F9-4D81-8F80-85DBAC6C6B8BQ95274318-9627F5B8-218E-4F7E-B3C3-502A8B26BC2B
P50
description
investigador
@es
researcher
@en
name
J H Trembley
@en
type
label
J H Trembley
@en
prefLabel
J H Trembley
@en
P31
P496
0000-0003-3597-2611